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Introduction: Prothrombin complex concentrate (PCC) and recombinant Factor VIIa (rFVIIa) have been used for
emergent reversal of warfarin anticoagulation. Few clinical studies have compared these agents in warfarin reversal.
We compared warfarin reversal in patients who received either 3 factor PCC (PCC3) or low-dose rFVIIa (LDrFVIIa) for
reversal of warfarin anticoagulation.
Methods: Data were collected from medical charts of patients who received at least one dose of PCC3 (20 units/
kg) or LDrFVIIa (1000 or 1200 mcg) for emergent warfarin reversal from August 2007 to October 2011. The primary
end-points were achievement of an INR 1.5 or less for efficacy and thromboembolic events for safety.
Results: Seventy-four PCC3 and 32 LDrFVIIa patients were analyzed. Baseline demographics, reason for warfarin reversal,
and initial INR were equivalent. There was no difference in the use of vitamin K or fresh frozen plasma. More
LDrFVIIa patients achieved an INR of 1.5 or less (71.9% vs. 33.8%, p =0.001). The follow-up INR was lower after
LDrFVIIa (1.25 vs. 1.75, p < 0.05) and the percent change in INR was larger after LDrFVIIa (54.1% vs. 38.8%, p = 0.002). There
was no difference in the number of thromboembolic events (2 LDrFVIIa vs. 5 PCC3, p = 1.00), mortality, length of hospital
stay, or cost.
Conclusions: Based on achieving a goal INR of 1.5 or less, LDrFVIIa was more likely than PCC3 to reverse warfarin
anticoagulation. Thromboembolic events were equivalent in patients receiving PCC3 and LDrFVIIa.
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Bleeding complications continue to be an important risk
of warfarin anticoagulation.
Despite this risk, warfarin continues to be a widely used
anticoagulant for outpatient management of patients who
have suffered a deep vein thrombosis with or without pul-
monary embolism, or who require prophylaxis against a
thromboembolic event associated with atrial fibrillation or
prosthetic valves. Furthermore, as the population con-
tinues to age, the number of patients receiving warfarin is* Correspondence: chapm004@umn.edu
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unless otherwise stated.increasing and this correlates with a rise in the incidence
of complications associated with warfarin anticoagulation.
This ultimately results in an increase in risk for bleeding
and associated morbidity and mortality for patients. In a
pooled analysis of 3665 patients receiving warfarin antic-
oagulation (goal international normalized ratio [INR] 2.0-
3.0) for nonvalvular atrial fibrillation in the SPORTIF III
and V trials, the annual incidence of major bleeding and
associated mortality was 2.68% and 8.09%, and the inci-
dence of intracerebral bleeding and associated mortality
was 0.19% and 45.4% [1].
Patients who suffer severe or life-threatening bleeding
complications during warfarin anticoagulation require
rapid normalization of their coagulation status in an at-
tempt to minimize bleeding and the associated morbid-
ity. Traditionally, this is achieved by transfusion of freshral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Subject selection. PCC3, 3 factor prothrombin complex
concentrate; LDrFVIIa, low dose recombinant factor VII activated.
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factors and administering vitamin K. Disadvantages of
FFP includes the large volume of fluid required, the time
required to thaw, the time need for blood group match-
ing, and the risk for transfusion reactions, transmission
of infections and transfusion related lung injury. For
intravenous vitamin K there is a small risk of anaphyl-
axis (3 per 10,000 patients) [2]. Finally, both strategies
require significant time to normalize the patient’s INR
(median time > 8–32 hours for FFP and > 24 hours for
vitamin K) [3-9].
The coagulation factors prothrombin complex concen-
trate (PCC) and recombinant factor VII activated (rFVIIa)
have both been used for the reversal of warfarin anticoagu-
lation. Both can be administered more quickly and can
provide more rapid reversal of warfarin anticoagulation
as defined by normalization of the INR [10-14]. The
doses of PCC and rFVIIa administered in these reports
has varied widely and thus the optimal dose for reversal
of warfarin anticoagulation with these products is un-
known. Additionally, there is little information about
potential differences in the efficacy and safety of rFVIIa
when compared with PCC.
There is limited data in the literature reporting a com-
parison of PCC and rFVIIa for warfarin anticoagulation
reversal [14]. Our institution uses both a 3 factor PCC
(PCC3) weight based doses at 20 units/kg regardless of
INR and low dose rFVIIa (LDrFVIIa) 1000 mcg or 1200
mcg for serious and life-threatening bleeding in patients
anticoagulated with warfarin. To evaluate these therapies,
we reviewed the charts of patients who required emergent
reversal of warfarin anticoagulation and who received either
PCC as a 3 factor product (PCC3) or LDrFVIIa to compare
the safety and efficacy of these coagulation factor products.
Our hypothesis was that PCC3 and LDrFVIIa are equally
effective and safe for warfarin anticoagulation reversal.
Methods
Institutional review board approval was obtained and a
retrospective chart review was conducted at North
Memorial Medical Center, an American College of
Surgeons verified level 1 trauma center. The electronic
medical record database was searched to identify all pa-
tients who received either PCC or rFVIIa from August
29th, 2007 to October 10th, 2011. A review of the elec-
tronic medical record of those patients was conducted to
identify patients who met the following inclusion criteria:
Clear documentation of warfarin usage prior to admission,
a need for emergent reversal of warfarin anticoagulation
and a pre-reversal INR of 1.6 or greater, received either
prothrombin complex concentrate (PCC3, 20 units/kg
rounded to nearest 500 units) or low-dose recombinant
Factor VIIa (LDrFVIIa, 1000 or 1200 mcg), and at least
one INR obtained pre and one INR obtained postcoagulation factor administration. Fresh frozen plasma
and vitamin K were administered at provider discretion. Pa-
tients were excluded if they had no pre or post coagulation
factor INR, a pre-reversal INR of 1.5 or less, received both
PCC3 and LDrFVIIa, received more than one PCC3 or
rFVIIa dose before follow-up INR, or received any single
rFVIIa dose greater than 1200 mcg. The PCC3 product
used was Profilnine® SD (Grifols Biologicals Inc., Los
Angeles, CA) and the rFVIIa product was NovoSeven®
or NovoSeven RT® (Novo Nordisk Inc., Princeton, NJ).
The following data were collected: 1) Demographic: age,
gender, indication for warfarin, and indication for reversal;
2) Coagulation parameters: INR pre and post administra-
tion of either PCC3 or LDrFVIIa, change in INR (absolute
and percent change), achievement at INR of 1.5 or less, and
time to reach INR 1.5 or less; 3) Reversal agent administra-
tion and cost: PCC3, LDrFVIIa, FFP, vitamin K; 4) Patient
outcome: Mortality, hospital length of stay, survivor length
of stay, and incidence and type of thromboembolic event.
There was no systematic schedule for INR monitoring after
the administration of reversal agents, and repeat doses of
coagulation factors were administered at the treating
provider’s discretion based on the follow-up INR after
the first dose. There was no systematic screening for
thromboembolic events; patients were assessed for any
potential thromboembolic complications as was deemed
clinically appropriate.
Table 1 Baseline demographic characteristics of the study
patients
Characteristics PCC3 (n = 74) LD rFVIIa (n = 32) p
Demographics
Age (years)* 73 [62.3-81.0] 67 [59.5-79.3] 0.32
M:F 43:31 22:10 0.39
Indication for Warfarin, n*,#, **, ***
Atrial arrhythmia 44 19 0.99
Cardiomyopathy 2 1 1.00
Valve replacement 11 7 0.38
Ischemic CVA 2 2 0.58
DVT/PE
Treatment*# 18 6 0.53
Prophylaxis 11 3 0.55
Portal vein thrombosis 0 1 0.30
Hyperhomocysteinemia 1 0 1.00
Lupus Anticoagulant 1 0 1.00
Syndrome
Unknown 1 0 1.00
*2 with Protein S deficiency # 2 with Anticardiolipin Syndrome.
**5 with 2 indications ***5 with 2 indications.
*Data reported as median [IQR].
PCC3, 3 factor prothrombin complex concentrate; LDrFVIIa, low dose recombinant
factor VII activated; CVA, cerebral vascular accident; DVT, deep vein thrombosis;
PE, pulmonary embolism.
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mine if differences were statistically significant for the
above-mentioned demographic, coagulation, and outcome
parameters, with the primary efficacy end-point being
achievement of goal INR less than or equal to 1.5, and the
primary safety end-point being number of thromboembolic
events. Statistical tests utilized include the Wilcoxon Rank
Sum test to compare continuous data, reported as median
[IQR], and Chi Square or Fisher exact test for categorical
data, reported as n, %. A p value less than or equal to 0.05
was considered statistically significant.
Results
Based on inclusion and exclusion criteria, 74 PCC3
patients and 32 LDrFVIIa patients were included in
the final analysis (Figure 1). There were no significant dif-
ferences between the groups with regards to age, gender,
or indication for anticoagulation with warfarin (Table 1).
There was also no difference in the indication for emergent
reversal (Table 2), except for more patients who presented
with subdural hematoma received LDrFVIIa. The groups
were similar with regards to the percentage of patients re-
ceiving vitamin K (77.0% PCC3 vs. 68.8% LDrFVIIa,
p = 0.37) or FFP (66.2% PCC3 vs. 65.6% LDrFVIIa p =
0.95), and the number FFP units administered (2[0-4]
PCC3 vs. 2[0-4] LDrFVIIa, p = 0.75) (Table 3). The initial
dose of PCC3 was 1540[1429-1978] units or 19.9 [18.6-
20.8] units/kg, and the dose of LDrFVIIa was 1000[1000-
1000] mcg or 11.5 [10.1-15.0] mcg/kg. Table 4 details the
INR response comparing the two coagulation factors. Base-
line INRs were equivalent for the two groups prior to the
first dose of either PCC3 or LDrFVIIa (3.1[2.3-4.1] PCC3
vs. 2.8[2.2-3.6] LDrFVIIa, p = 0.52). After one dose of co-
agulation factor, 71.9% of patients in the LDrFVIIa group
achieved goal INR of 1.5 or less compared to 33.8% in the
PCC3 group (p = 0.001). The time between pre and post
coagulation factor INRs was similar (3:53[2:32-7:17]) in
PCC3 group and 4:30[2:21-6:25] in LDrFVIIa group,
p = 0.78). The percent change in INR was higher after
administration of LDrFVIIa compared to PCC3 (54.1%
[47.3%-62.7%] for the LDrFVIIa group vs. 38.8% [30.7%-
56.0%] for the PCC3 group, p = 0.002).
Five thromboembolic events occurred in the PCC3
group compared to 2 events in the LDrFVIIa group
(Table 5, p = 1.00). Deep vein thrombosis (DVT) occurred
in 2 patients in each group. In the PCC3 group, one pa-
tient was found to have 4 upper extremity DVTs 7 days
after PCC3 administration, and the other was found to
have a superior femoral vein DVT 5 days after PCC3 ad-
ministration. In the LDrFVIIa group, one patient had a
lower extremity DVT 11 days after LDrFVIIa administra-
tion, and the other was found to have a left upper extrem-
ity non- occlusive DVT 7 days post-LDrFVIIa. All DVTs
diagnosed by duplex ultrasonography. Three PCC3patients experienced an additional thromboembolic com-
plication during their hospitalization: right internal jugular
vein thrombus 15 days post-PCC3 (central line present),
MRI-confirmed cerebrovascular accident (CVA) with mul-
tiple infarcts 2 days post-PCC3, and chest tube clots 1 day
post-PCC3 (this patient may have also had a CVA which
could have contributed to death, although this was not
confirmed with imaging).
There was no difference in mortality (29.7% PCC3 vs.
18.8% LDrFVIIa, p = 0.34), overall length of hospital stay
[PCC3 group 8.0 [4-11] days vs. LDrFVIIa group 7.5 [5-
13] days (p = 0.43)] or length of stay of survivors [PCC3
group 8.0 [4-11] days vs. LDrFVIIa group 9.5 [6-13], p =
0.15]. Coagulation factor cost (USD) was not different
(1116.50 [963-1718] in the PCC3 group, and 1230[1170-
1360] in the LDrFVIIa group, p = 0.26) and FFP cost
(USD) was similar between the two groups (393[0-496]
in the PCC3 group and 393[0-496] in the LDrFVIIa
group, p = 0.70). However, when combined, the overall
cost for FFP and coagulation factor was higher in the
PCC3 group (1526 [1299-2047] PCC3 vs. 1609.50 [1360-
1756] LDrFVIIa, p < 0.05).
Discussion
Administration of PCC or rFVIIa for the reversal of war-
farin anticoagulation in emergent or life-threatening
bleeding has been reported in several publications, yet






Neuro, n* 39 23 0.07
CH 19 9 0.79
SDH 7 9 0.014
SAH 6 2 1.00
SCI 1 2 0.22
TBI 6 1 0.67
Craniotomy 0 1 0.30
Abdominal 11 3 0.55
Intraperitoneal Hem. 2 0 1.00
Retroper. hematoma 1 0 1.00
GIB 2 1 1.00
Perf. Viscous/ 0 1 0.30
peritonitis
Pneumoperitoneum 1 0 1.00
Incarcerated hernia 2 1 1.00
Acute abdomen 1 0 1.00
Diverticulitis 1 0 1.00
Colonic perforation 1 0 1.00
Other 25 8 0.37
Orthopedic 2 3 0.16
Fall w/external inj. 0 1 0.30
Multiple trauma 0 1 0.30
Pulmonary contusion 1 0 1.00
Chest wall trauma 1 0 1.00
Pacemaker placement 2 0 1.00
Emergent surgery 4 1 1.00
Ruptured iliac 1 0 1.00
Artery aneurysm
Pseudoaneurysm 1 0 1.00
CFA
Hematoma 3 0 1.00
Pneumothorax 2 0 1.00
Posthemorrhagic 1 0 1.00
Hydrocephalus
Epistaxis 0 1 0.30
INR > 8 6 0 0.18
Unknown 1 0 1.00
*1 with more than 1 indication.
PCC3, 3 factor prothrombin complex concentrate; LDrFVIIa, low dose
recombinant factor VII activated; ICH, intracranial hemorrhage, SDH,
subdural hematoma, SAH, subarachnoid hemorrhage, SCI, spinal cord
injury, TBI, traumatic brain injury, GIB, gastrointestinal bleed, CVA,
cerebral vascular accident; DVT, deep vein thrombosis; PE, pulmonary
embolism.









Total Dose (units)* 1540 [1429-1978] 1000 [1000-1000] NA
Weight-based Dose
(units/kg)*
19.9 [18.6-20.8] 11.5 [10.1-15.0] NA
Other reversal agents
administered
Vit K, n (%) 57 (77.0%) 22 (68.8%) 0.37
FFP, n (%) 49 (66.2%) 21 (65.6%) 0.95





1116.50 [963-1718] 1230 [1170-1360] 0.26
FFP(USD)*: 393 [0-496] 393 [0-496] 0.65
Total(USD)*: 1526 [1299-2047] 1609.50 [1360-1756] <0.05
*Data as median [IQR].
PCC3, 3 factor prothrombin complex concentrate; LDrFVIIa, low dose
recombinant factor VII activated; kg, kilograms; FFP, fresh frozen plasma; vit K,
vitamin K, USD, United States Dollars).
Chapman et al. World Journal of Emergency Surgery 2014, 9:27 Page 4 of 7
http://www.wjes.org/content/9/1/27there is uncertainty as to their safety or efficacy, and the
appropriate doses of these agents to administer. Our
findings indicate that LDrFVIIa (1000 or 1200 mcg) is
more effective at reversing the INR compared to PCC3
(20 units/kg) as evident by more patients achieving an
INR of 1.5 or less. Furthermore, only one patient receiv-
ing LDrFVIIa required a second dose for additional war-
farin reversal, compared to 16 PCC3 patients who
received a second dose, all of these due to failure of the
first dose to effectively reverse the INR to 1.5 or less.
There was no difference in mortality or thromboembolic
complications, although the small sample size makes this
difficult to interpret. Further, no association can be made
from this data as to whether the thromoboembolic
events were the result of the coagulation factor adminis-
tered independent of other existing risk factors for
thromboembolic events.
Prothrombin complex concentrate products are de-
rived from purified pooled human plasma. All PCC
products contain factors II, IX, and X along with variable
amounts of factor VII. Some PCC products, referred to
as 4 factor PCC, contain larger amounts of factor VII
(36–100 I.U. per 100 I.U. factor IX) compared to PCC3
products, that contain relatively low amounts of factor
VII (0–25 I.U. per 100 I.U. factor IX) [11]. Both PCC3
products (dosed at 12–50 units/kg) and 4 factor PCC
products (dosed at 7–50 units/kg) have been reported to
provide rapid reversal of the INR [11]. Two PCC prod-
ucts available in the United States (Profilnine® SD and











1.75 [1.5-2.0] 1.25 [1.0-1.25] <0.05
INR Δ*: 1.2 [0.7-2.2] 1.5 [1.2-2.0] 0.14
% Δ INR*: 38.8% [30.7%-56.0%] 54.1% [47.3%-62.7%] 0.002
n (%)≤ 1.5: 25 (33.8%) 23 (71.9%) 0.001
Time (h:mm)*: 3:53 [2:32-7:17] 4:30 [2:21-6:25] 0.78
*Data as median [IQR].
PCC3, 3 factor Prothrombin Complex Concentrate; LDrFVIIa, low dose
recombinant factor VII activated; INR, International Normalized Ratio.
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standardized dosing regimen at the time of this work
and the wide range of doses of PCC reported in the lit-
erature, we chose 20 units/kg as an initial PCC dose
with recommendations to repeat the INR post-PCC3 ad-
ministration. A 4 factor PCC product available in Europe
has completed clinical trials and has recently been ap-
proved by the FDA (Kcentra®) for warfarin reversal in
patients with acute major bleeding. When compared
with plasma, this 4 factor PCC product was found to be
non-inferior at achieving hemostasis at 24 hours (72.4%
vs. 65.4%) and superior at achieving rapid correction of
INR to 1.3 or less at 30 minutes (62.2% vs. 9.6%). The
recommended dosing strategy for this product is 25–50
units/kg based on patient weight and baseline INR [15].
The fixed dosing used in our patients may have contrib-
uted to the results of fewer patients achieving the goal
INR of 1.5 or less.
A recent evaluation of PCC3 found suboptimal rever-
sal of warfarin in patients with an INR greater than 5.
The INR was reversed to less than 3 in 50% of patientsTable 5 Patient outcomes
PCC3 (n = 74) LD rFVIIa (n = 32) p
Mortality, n (%) 22 (29.7%) 6 (18.8%) 0.34
LOS all pts (d)* 8.0 [4-11] 7.5 [5-13] 0.43
LOS survivors (d)* 8.0 [4-11] 9.5 [6-13] 0.15
Thromboembolic events 5 2 1.00
DVT 2 2
IJ thrombus 1 0
Multiple CVA’s 1 0
Chest tube clots 1 0
(and possible unconfirmed CVA)
*Data as median [IQR].
PCC3, 3 factor prothrombin complex concentrate; LDrFVIIa, low dose
recombinant factor VII activated; LOS, length of stay; DVT, deep vein
thrombosis, IJ, internal jugular; CVA, cerebral vascular accident.receiving PCC3 25 units/kg and 43% of patients receiv-
ing PCC 50 units/kg. Transfusion of additional FFP
(mean of 2.1) was required to provide further INR low-
ering to below 3, resulting in 89% and 88% of patients in
the 25 U/kg and 50 U/kg groups achieving that INR
goal, respectively [16]. Imberti et al. used a PCC3 admin-
istered at 35–50 units/kg in patients with ICH effectively
reversed the INR from a mean of 3.5 (range 2.0–9.0) to
1.3 (range 0.9-3.0) with 75% of patients achieving an
INR of less than 1.5 within 30 minutes of PCC3 admin-
istration. These authors also noted achieving an INR less
than 1.5 within 30 minutes fewer in patients whose INR
was 4–6 (33%) compared to those whose INR was 2.0-
3.9 (89%) [17]. These results led some to suggest that
PCC3 use be limited to patients whose INR is 4 or less
until further data on PCC3 use in higher INR levels is
available [18].
Recombinant factor VII, when complexed with tissue
factor, accelerates the extrinsic clotting cascade to promote
coagulation. Several reports, mostly in patients who have
suffered acute intracranial hemorrhage secondary to war-
farin anticoagulation, reported rFVIIa dosed at 10–100
mcg/kg or 1200–9600 mcg to rapidly and completely
reversed the INR [5,19-22]. In a study evaluating lower
doses of rFVIIa for warfarin reversal, Dager et al. reported
that 16 patients who received 1200 mcg of rFVIIa effect-
ively achieved reversal of the INR a mean INR of 2.8 to
1.07 in a mean time of 35 minutes [13].
Our results show that both PCC3 and LDrFVIIa re-
verse warfarin anticoagulation, but that LDrFVIIa was
more predictable at complete reversal of the INR. We used
Profilnine® SD, PCC3 containing not more than 35 I.U. of
factor VII per 100 units of factor IX [23]. The lower
amounts of factor VII may have resulted in smaller reduc-
tions in the INR which is highly sensitive to inhibition by
factor VII and may not have reflected its true effect on the
coagulation system. In contrast, LDrFVIIa rapidly and
completely reversed the INR in our patients.
Whether this is due to the sensitivity of the INR to
factor VII activity or whether it reflects the true effect
on the coagulation system can only by inferred from our
data in that there were no cases of unexpected bleeding in
either group. Skolnick et al. provided data that questions
whether the INR is the most accurate test to measure the
true anticoagulation reversal effects of coagulation factors
and the ability of rFVIIa to completely reverse warfarin
anticoagulation. In a study evaluating the effects of rFVIIa
on coagulation parameters and bleeding from punch biop-
sies in 85 study subjects anticoagulated with warfarin (INR
was 2.5 ± 0.3). Subjects underwent biopsies at 4 time points:
1) prior to warfarin anticoagulation; 2) after an INR of 2.5
or greater was achieved; 3) 13 minutes after receiving an in-
jection of placebo or one dose of rFVIIa (administered
2 hours after the second biopsy) as either 5, 10, 20, 40, or
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administered. Coagulation parameters aPTT, PT, and INR
and thrombin generation were collected in all patients at
each biopsy. The mean INR was significantly lower in those
patients that receiving rFVIIa at all doses (1.2-1.5) when
compared to those that receiving placebo (2.5), p < 0.001.
However, bleeding duration (min) and blood loss (ml) were
not different between those who received placebo and those
who received rFVIIa at any dose [24].
To compare the effects of rFVIIa and PCC on anticoagu-
lation reversal, Dickneite administered saline, 100 mcg/kg
rFVIIa, or PCC 50 units/kg (Beriplex® P/N-a 4 factor PCC)
in rats anticoagulated with either one dose of 2.5 mg/kg
phenprocoumon (acute model) or two doses of phenpro-
coumon dosed 24 hours apart (sustained model). Anticoa-
gulation was reversed 16 hours after the single dose model
or 48 hours after the 2 dose model. Both rFVIIa and PCC4
were effective at lowering the PT compared to placebo.
However, in the sustained model, PCC4 was significantly
more effective at reducing blood loss compared to placebo
and rFVIIa [25]. The author suggests the difference in the
results are due to the low levels of other clotting factors,
aside from factor VII, in rFVIIa compared to this PCC4
product. In the 9th edition of the American College of
Chest Physicians Evidence Based Clinical Practice Guide-
lines on the Pharmacology and Management of Vitamin K
Antagonists released in February 2012, a specific recom-
mendation was made to prefer four-factor PCC over FFP
for rapid reversal of anticoagulation in VKA-associated
major bleeding [10]. Due to limited evidence supporting
rFVIIa, the guidelines also state that rFVIIa cannot be rec-
ommended unless other more effective agents are not avail-
able in the setting of life threatening bleeding [3].
The administration of coagulation factors is associated
with thromboembolic events. In our study groups, the inci-
dence of thromboembolic events was equal in both groups.
Safaoui et al. reported no thromboembolic events in 28 pa-
tients receiving 2000 units of PCC3 (Konyne™ or Profil-
nine™) [26]. In a recent case report a dose of 50 units/kg of
PCC for warfarin reversal was associated with fatal intracar-
diac thrombosis in a patient who had also received 24 mi-
crograms of desmopressin for suspected uremic platelet
dysfunction and fifty minutes later underwent pericardio-
centesis [27]. There is more literature addressing the risk of
thromboembolic events associated with rFVIIa. A recent
publication evaluated 35 randomized clinical trials involving
4468 patients. A total of 498 thromboembolic events were
reported (11.1%). Arterial thrombembolic events were
higher in those that received rFVIIa (5.5% rFVIIa vs. 3.2%
Placebo, p = 0.003), particularly coronary events (2.9% vs.
1.1%, p = 0.002). Venous thromboembolic events were not
different between rFVIIa and placebo (5.3% rFVIIa vs. 5.7%.
placebo) [28]. There were no arterial thromboembolic
events in any of the patients in our study groups.There were several limitations to our study. This was a
retrospective, observational study at a single center in
which the choice of coagulation factor was at the discretion
of the prescriber and INR monitoring was not conducted in
accordance to any protocol. While the average time be-
tween the pre and post coagulation factor INR was similar
in the two groups (3:53[2:32-7:17] PCC3 compared to 4:30
[2:21-6:25] LDrFVIIa, p = 0.78), the lack of standardization
prevents us from determining the actual timing of INR re-
versal. It is possible that some patients achieved a goal INR
of less than or equal to 1.5 in a significantly shorter time
period given the observation that coagulation factor levels
would be expected to rise quickly after administration
rFVIIa or PCC and a literature review of 4-factor PCC cor-
rected the INR within 10 to 20 minutes of administration
[9]. Another limitation of this study is that there was no
scheduled or systematic screening for thromboembolic
events. Although patients receiving PCC and rFVIIa are
generally assessed for signs of thromboembolic complica-
tions, events could have gone undetected.
Conclusions
In patients with serious or life threatening bleeding, low
dose activated recombinant factor VII provided a more
rapid and complete reversal of warfarin anticoagulation
as determined by reduction of the INR to a value of 1.5
or less when compared to 3 factor prothrombin complex
concentrate. The effect on systemic coagulation cannot
be determined by this study since we did not measure
coagulation factor concentrations or bleeding time in
correlation with the INR. Thromboembolic events were
not different between the groups. LDrFVIIa and PCC3
groups were comparable in terms of cost for reversal
therapies. Further research is needed to provide greater
information about the impact of coagulation factor con-
centration changes related to the administration of coagu-
lation factors, the effect these products have on restoring
normal coagulation and at different doses, and the true
impact of these products on the actual impact of restoring
hemostasis.
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